Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Irmandade da Santa Casa de Misericordia de Sao Paulo
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02467686CT.gov Breast Cancer, Sexuality and Black Cohosh | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sexual Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Exemestane (this asset) | Irmandade da Santa Casa de Misericordia de Sao Paulo | Approved | BB · 64 |
| Tadalafil | University of Roma La Sapienza | P4 | BBB |
| Testosterone Undecylate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Risperidone | Si Tianmei | P4 | BB |
| Cimicifuga Racemosa | Irmandade da Santa Casa de Misericordia de Sao Paulo | P4 | BB |
| Paliperidone | Si Tianmei | P4 | BB |
| Tamoxifen | Irmandade da Santa Casa de Misericordia de Sao Paulo | P4 | BB |
| Leuporelin | University College, London | P3 | BB |
| Goserelin | University College, London | P3 | BB |
+19 more in the Sexual Disorder cohort
Other indications for Exemestane
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Positive Breast Cancer | — | P4 | BBB · 75 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Her2-Receptor Negative Breast Cancer | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Exemestane in Sexual Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/exemestane-sexual-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →